221 related articles for article (PubMed ID: 30226466)
21. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata.
Eggert SL; Huyck KL; Somasundaram P; Kavalla R; Stewart EA; Lu AT; Painter JN; Montgomery GW; Medland SE; Nyholt DR; Treloar SA; Zondervan KT; Heath AC; Madden PA; Rose L; Buring JE; Ridker PM; Chasman DI; Martin NG; Cantor RM; Morton CC
Am J Hum Genet; 2012 Oct; 91(4):621-8. PubMed ID: 23040493
[TBL] [Abstract][Full Text] [Related]
23. Evidence of a causal effect of genetic tendency to gain muscle mass on uterine leiomyomata.
Sliz E; Tyrmi JS; Rahmioglu N; Zondervan KT; Becker CM; ; Uimari O; Kettunen J
Nat Commun; 2023 Feb; 14(1):542. PubMed ID: 36726022
[TBL] [Abstract][Full Text] [Related]
24. Allelotype of uterine leiomyomas.
Mao X; Barfoot R; Hamoudi RA; Easton DF; Flanagan AM; Stratton MR
Cancer Genet Cytogenet; 1999 Oct; 114(2):89-95. PubMed ID: 10549262
[TBL] [Abstract][Full Text] [Related]
25. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
[TBL] [Abstract][Full Text] [Related]
26. A View on Uterine Leiomyoma Genesis through the Prism of Genetic, Epigenetic and Cellular Heterogeneity.
Koltsova AS; Efimova OA; Pendina AA
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982825
[TBL] [Abstract][Full Text] [Related]
27. A variant of TP53 gene (rs 1625895, 13494g>A) is associated with neoplasm localization in patients with uterine leiomyoma.
Kornatska AG; Flaksemberg МА; Chubei GV; Trokhymovych ОV; Rossokha ZI; Fishchuk LY; Medvedieva NL; Vershyhora VO; Gorovenko NG
Exp Oncol; 2021 Jun; 43(2):155-158. PubMed ID: 34190520
[TBL] [Abstract][Full Text] [Related]
28. Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.
He C; Nelson W; Li H; Xu YD; Dai XJ; Wang YX; Ding YB; Li YP; Li T
Reprod Sci; 2022 Feb; 29(2):357-365. PubMed ID: 33569750
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis.
Gallagher CS; Mäkinen N; Harris HR; Rahmioglu N; Uimari O; Cook JP; Shigesi N; Ferreira T; Velez-Edwards DR; Edwards TL; Mortlock S; Ruhioglu Z; Day F; Becker CM; Karhunen V; Martikainen H; Järvelin MR; Cantor RM; Ridker PM; Terry KL; Buring JE; Gordon SD; Medland SE; Montgomery GW; Nyholt DR; Hinds DA; Tung JY; ; Perry JRB; Lind PA; Painter JN; Martin NG; Morris AP; Chasman DI; Missmer SA; Zondervan KT; Morton CC
Nat Commun; 2019 Oct; 10(1):4857. PubMed ID: 31649266
[TBL] [Abstract][Full Text] [Related]
30. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility Risk Alleles of -238G/A, -308G/A and -1031T/C Promoter Polymorphisms of TNF-α Gene to Uterine Leiomyomas.
Medikare V; Ali A; Ananthapur V; Deendayal M; Nallari P
Recent Adv DNA Gene Seq; 2015; 9(1):65-71. PubMed ID: 26467281
[TBL] [Abstract][Full Text] [Related]
32. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
Heinonen HR; Pasanen A; Heikinheimo O; Tanskanen T; Palin K; Tolvanen J; Vahteristo P; Sjöberg J; Pitkänen E; Bützow R; Mäkinen N; Aaltonen LA
Sci Rep; 2017 Apr; 7(1):1015. PubMed ID: 28432313
[TBL] [Abstract][Full Text] [Related]
33. MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.
Markowski DN; Bartnitzke S; Löning T; Drieschner N; Helmke BM; Bullerdiek J
Int J Cancer; 2012 Oct; 131(7):1528-36. PubMed ID: 22223266
[TBL] [Abstract][Full Text] [Related]
34. Uterine Leiomyomas with an Apparently Normal Karyotype Comprise Minor Heteroploid Subpopulations Differently Represented in vivo and in vitro.
Koltsova AS; Efimova OA; Pendina AA; Chiryaeva OG; Osinovskaya NS; Shved NY; Yarmolinskaya MI; Polenov NI; Kunitsa VV; Sagurova YM; Tral TG; Tolibova GK; Baranov VS
Cytogenet Genome Res; 2021; 161(1-2):43-51. PubMed ID: 33550288
[TBL] [Abstract][Full Text] [Related]
35. Selective genetic analysis of myoma pseudocapsule and potential biological impact on uterine fibroid medical therapy.
Di Tommaso S; Massari S; Malvasi A; Vergara D; Maffia M; Greco M; Tinelli A
Expert Opin Ther Targets; 2015 Jan; 19(1):7-12. PubMed ID: 25363374
[TBL] [Abstract][Full Text] [Related]
36. Not so benign.
Rivera B
Elife; 2018 Oct; 7():. PubMed ID: 30362943
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor alpha polymorphism and susceptibility to uterine leiomyoma.
Villanova FE; Andrade PM; Otsuka AY; Gomes MT; Leal ES; Castro RA; Girão MJ; Nishimura E; Baracat EC; Silva ID
Steroids; 2006 Nov; 71(11-12):960-5. PubMed ID: 16935316
[TBL] [Abstract][Full Text] [Related]
38. Med12 gain-of-function mutation causes leiomyomas and genomic instability.
Mittal P; Shin YH; Yatsenko SA; Castro CA; Surti U; Rajkovic A
J Clin Invest; 2015 Aug; 125(8):3280-4. PubMed ID: 26193636
[TBL] [Abstract][Full Text] [Related]
39. Molecular and Cellular Insights into the Development of Uterine Fibroids.
Machado-Lopez A; Simón C; Mas A
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445194
[TBL] [Abstract][Full Text] [Related]
40. [MED12 gene mutations in women with uterine myoma].
Osinovskaya NS; Ivashchenko TE; Dolinskii AK; Sultanov IY; Ghimbovchi S; Hoffman E; Bezhenar VF; Baranov VS
Genetika; 2013 Dec; 49(12):1426-31. PubMed ID: 25438604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
